Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
about
Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits.Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy.The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
P2860
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@en
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@nl
type
label
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@en
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@nl
prefLabel
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@en
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@nl
P2093
P1476
Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
@en
P2093
Akiko Yamamoto
Kazuyoshi Kato
Kenji Umayahara
Kohei Omatsu
Maki Matoda
Nobuhiro Takeshima
Norichika Ushioda
Sanshiro Okamoto
Terumi Tanigawa
Yasutaka Kawamata
P304
P356
10.1097/IGC.0B013E3182A80A07
P577
2013-11-01T00:00:00Z